Literature DB >> 35142365

The clinicopathological and prognostic significances of LATS1 expression in breast cancer.

Hua-Chuan Zheng1, Li-Wei Xiang2, Zheng-Guo Cui3, Hang Xue2, Ying E4, Ming-Zhen Zhao5.   

Abstract

AIM: Large tumor suppressor gene 1 (LATS1) belongs to the PKA/PKG/PKC serine/threonine kinase subfamily of the Hippo signaling pathway and inactivates nuclear co-activators YAP1 and WWTR1 by phosphorylation. This study aimed to discern the clinicopathological and prognostic significances of LATS1 expression in breast cancer.
METHODS: We examined LATS1 expression in breast carcinogenesis and compared it with clinicopathological parameters and survival information of breast cancer patients using immunohistochemistry, western blotting, RT-PCR, and bioinformatics analysis.
RESULTS: LATS1 expression was downregulated in breast cancer at both mRNA and protein levels (P<0.05). LATS1 mRNA expression was negatively correlated with low ER and PR expression, aggressive subtypes (TNBC and HER2+ vs. luminal), and poor survival (P<0.05). Its protein expression was negatively linked to patient age, T stage, N stage, M stage histological grade, PR status, and unfavorable prognosis (P<0.05). There was a positive correlationship between nuclar and cytoplasmic LATS1 expression in breast cancer (P<0.05).
CONCLUSIONS: The downregulation of LATS1 expression plays a vital role in the carcinogenesis and progression of breast cancer. Thus, LATS1 loss was employed to indicate the aggressive behaviors and poor prognosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35142365     DOI: 10.14670/HH-18-433

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.130


  58 in total

1.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

2.  Breast cancer statistics, 2019.

Authors:  Carol E DeSantis; Jiemin Ma; Mia M Gaudet; Lisa A Newman; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-10-02       Impact factor: 508.702

3.  Methylation‑associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.

Authors:  Ke-Hong Chen; Jiang He; De-Lin Wang; Jian-Jia Cao; Mei-Cai Li; Xiu-Min Zhao; Xia Sheng; Wen-Bin Li; Wu-Jiang Liu
Journal:  Int J Oncol       Date:  2014-09-30       Impact factor: 5.650

Review 4.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

5.  Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.

Authors:  Jacob J Adler; Derrick E Johnson; Brigitte L Heller; Lauren R Bringman; William P Ranahan; Michael D Conwell; Yang Sun; Andy Hudmon; Clark D Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

6.  The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.

Authors:  Adrian Britschgi; Stephan Duss; Sungeun Kim; Joana Pinto Couto; Heike Brinkhaus; Shany Koren; Duvini De Silva; Kirsten D Mertz; Daniela Kaup; Zsuzsanna Varga; Hans Voshol; Alexandra Vissieres; Cedric Leroy; Tim Roloff; Michael B Stadler; Christina H Scheel; Loren J Miraglia; Anthony P Orth; Ghislain M C Bonamy; Venkateshwar A Reddy; Mohamed Bentires-Alj
Journal:  Nature       Date:  2017-01-09       Impact factor: 49.962

7.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

8.  TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.

Authors:  Qianze Dong; Lin Fu; Yue Zhao; Chengyao Xie; Qingchang Li; Enhua Wang
Journal:  Oncotarget       Date:  2017-02-28

9.  LATS1 suppresses proliferation and invasion of cervical cancer.

Authors:  Jihong Deng; Wen Zhang; Shuangyue Liu; Hongmei An; Lu Tan; Lisha Ma
Journal:  Mol Med Rep       Date:  2017-02-08       Impact factor: 2.952

10.  The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients' Survival.

Authors:  J Godlewski; J Kiezun; B E Krazinski; Z Kozielec; P M Wierzbicki; Z Kmiec
Journal:  Biomed Res Int       Date:  2018-04-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.